NEW YORK, April 5, 2017 /PRNewswire/ --
Stock-Callers.com has issued research reports on four Drug Manufacturersstocks, which are: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Apricus Biosciences Inc. (NASDAQ: APRI), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). According to an article on The Daily Star, pharmaceutical companies
Shares in New York headquartered Synergy Pharmaceuticals Inc. saw a decline of 1.97%, ending Tuesday's trading session at $4.47. The stock recorded a trading volume of 3.93 million shares. The Company's shares are trading 13.20% below their 200-day moving average. Moreover, shares of Synergy Pharma, which focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders, have a Relative Strength Index (RSI) of 30.36.
On March 27th, 2017, Synergy Pharma announced that it has submitted a supplemental New Drug Application for TRULANCE™ (plecanatide) for the treatment of adults with irritable bowel syndrome with constipation. Visit us today and download your complete report on SGYP for free at:
Bagsvaerd, Denmark headquartered Novo Nordisk A/S' stock jumped 4.92%, closing the day at $36.05. A total volume of 6.15 million shares was traded, which was above their three months average volume of 2.40 million shares. The Company's shares have advanced 8.40% in the past month, 2.36% in the previous three months, and 2.54% since the start of this year. The stock is trading 6.25% above its 50-day moving average. Additionally, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 72.20.
On April 03rd, 2017, Novo Nordisk reported that the Company and its wholly owned affiliates on March 31st, 2017 owned 63,031,862 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 2,845,332,705, or 2.5% of the total share capital. In Q1 2017, a total of 17,934,545 B shares were repurchased, and 569,935 B shares were disposed to employees in connection with employee incentive programs. The complimentary research report on NVO can be accessed at:
On Tuesday, shares in San Diego, California headquartered Apricus Biosciences Inc. recorded a trading volume of 120,525 shares. The stock ended the day 2.37% lower at $2.06. The Company's shares have surged 50.36% in the previous three months and 58.46% on an YTD basis. The stock is trading below its 50-day moving average by 19.80%. Furthermore, shares of Apricus Biosciences, which focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology, have an RSI of 36.01.
On March 13th, 2017, Apricus Biosciences reported financial results for Q4 2016 and full-year 2016, and provided a corporate update on its priorities for 2017. Total revenues for the quarter and year-to-date periods ended December 31st, 2016, were $0.4 million and $5.8 million, respectively. Net loss for Q4 2016 was $0.3 million, and net loss for the year ended December 31st, 2016 was $7.4 million. Register for free on Stock-Callers.com and download the PDF research report on APRI at:
Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc.'s stock dropped 1.41%, finishing yesterday's session at $10.50, with a total trading volume of 820,553 shares. The Company's shares are trading below their 50-day moving average by 6.92%. Shares of the company, which focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the US, Japan, Switzerland, and internationally, have an RSI of 42.12.
On March 10th, 2017, research firm WallachBeth reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $20 a share to $15 a share.
On April 03rd, 2017, Sucampo Pharma announced that it has acquired Vtesse for upfront consideration of $200 million. The Company funded the acquisition through the issuance of 2,782,678 shares of Sucampo's Class A common stock and $170 million of cash on hand with no external financing utilized. Get free access to your research report on SCMP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!